NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing high-quality chemical compounds that drive innovation in the pharmaceutical sector. Gimeracil (CAS 103766-25-2) is one such compound, renowned for its critical role in improving the therapeutic outcomes of certain cancer treatments.

Gimeracil functions primarily as a potent inhibitor of dihydropyrimidine dehydrogenase (DPYD). DPYD is a key enzyme involved in the metabolic breakdown of pyrimidine-based compounds, including the widely used chemotherapy agent 5-fluorouracil (5-FU). By blocking the action of DPYD, Gimeracil prevents the rapid inactivation of 5-FU in the body. This inhibition leads to an increase in the plasma concentration and prolongs the systemic exposure to 5-FU. Such an effect is crucial for maximizing the cytotoxic impact of 5-FU on rapidly dividing cancer cells, thus improving treatment efficacy. The detailed understanding of the Gimeracil DPYD inhibitor mechanism is key to its therapeutic application.

This mechanism is particularly important when Gimeracil is used in combination with other drugs, such as in the oral chemotherapeutic regimen known as S-1. In this context, Gimeracil works alongside tegafur (a 5-FU prodrug) and oteracil. The presence of Gimeracil allows for a more efficient use of tegafur, as the resulting 5-FU remains active for longer periods. This enhances the overall anti-tumor effect and can allow for dose adjustments that potentially reduce side effects, such as gastrointestinal toxicity. The synergy achieved through Gimeracil enhancing 5-FU efficacy is a testament to its biochemical importance.

Beyond its primary role in chemotherapy, Gimeracil has also shown promise in other areas of cancer research. Preliminary studies suggest that it may play a role in sensitizing cancer cells to radiotherapy by interfering with DNA repair processes. This multifaceted activity underscores the compound's value in exploring new treatment modalities for various cancers.

As a leading supplier, NINGBO INNO PHARMCHEM CO.,LTD. ensures that our Gimeracil meets rigorous purity and quality specifications, making it suitable for pharmaceutical research and manufacturing. The precise Gimeracil synthesis and quality control are paramount to delivering a reliable intermediate. We empower pharmaceutical companies to develop effective anticancer drugs by providing them with this essential chemical building block.

For researchers and manufacturers interested in the applications of Gimeracil in advancing cancer therapy, we offer a consistent and high-quality supply. Explore the potential of this critical pharmaceutical intermediate and contribute to the development of more effective cancer treatments.